Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance

At present, treatment options for osimertinib resistance are very limited. Dual inhibition of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) significantly improved the progression-free survival (PFS) of advanced EGFR-mutant non–small cell lung cancer (NSCLC...

Full description

Bibliographic Details
Main Authors: Qingli Cui, Yanhui Hu, Qingan Cui, Daoyuan Wu, Yuefeng Mao, Dongyang Ma, Huaimin Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
osimertinib rechallenge
bevacizumab
EGFR
NSCLC
resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.746707/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.746707/full

Similar Items